Parabilis Medicines (PBLS) Posts 72% ORR in Early Zolucatetide Data; FDA Aligns on Phase 3 PFS
Parabilis Medicines (PBLS) reported 72.2% ORR and 100% DCR in Phase 1/2 zolucatetide data for desmoid tumors. FDA aligned on Phase 3 trial design, starting H1 2027, with topline results expected in 2029. Company to host investor webcast on October 24, 2026.
How this was made
The 30-second read
Why it matters
The disclosed data reduce regulatory and clinical risk, setting a clear path to a Phase 3 trial slated for H1 2027 with topline results expected in 2029.
Market read
First public disclosure of pivotal early‑stage data; likely to move PBLS stock on the news.
What to watch
Long timeline to readout (2029) may delay any price move; financing needs for Phase 3 could affect valuation.
Background
Parabilis Medicines is a clinical‑stage biotech developing zolucatetide for desmoid tumors. The company holds Fast Track and Orphan designations.
Ticker impact
Parabilis Medicines disclosed Phase 1/2 zolucatetide data showing 72.2% ORR and 100% DCR, and FDA alignment on Phase 3 design.
upward pressure as investors price in robust response rates and reduced trial risk
Phase 1/2 data are material for a biotech; the high ORR and FDA alignment typically lift the stock ahead of a Phase 3 launch.
Market effects
Positive signal for the desmoid‑tumor biotech niche and may boost peer biotech sentiment.
Limited to US‑listed biotech investors; no broader regional effect.
Minimal global impact beyond the biotech sector.
Counterpoint
If the Phase 3 trial fails to replicate early response rates, the stock could sharply decline.
Key entities
- companyParabilis Medicines
US‑listed biotech (ticker PBLS) reporting early trial results.